High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

Blood

Volumn 121, Issue 4, 2013, Pages 624-627

  Broyl, Annemiek ^a   Kuiper, Rowan ^a   Van Duin, Mark ^a   Van Der Holt, Bronno ^a   El Jarari, Laila ^a   Bertsch, Uta ^b   Zweegman, Sonja ^c   Buijs, Arjan ^d   Hose, Dirk ^b   Lokhorst, Henk M ^d   Goldschmidt, Hartmut ^b   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BORTEZOMIB; CEREBLON PROTEIN; CRBN PROTEIN; DDB1 PROTEIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT; MYC PROTEIN; PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHROMOSOME 3; DRUG EFFICACY; GENE EXPRESSION PROFILING; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

EID: 84873048466     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438101     Document Type: Article

References (18)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487- 2498.
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617.
3. Dimopoulos M, Spencer A, Attal M, et al. Lena-lidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21):2123-2132.
4. Weber DM, Chen C, Niesvizky R, et al. Lenalido-mide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.
5. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res. 2011;17(6):1253-1263.
6. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19): 1759-1769.
7. Attal M, Lauwers-Cances V, Marit G, et al. Lena-lidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-1791.
8. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3): 135-143.
9. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345-1350.
10. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-4779.
11. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase 3 HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30(24):2946-2955.
12. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
13. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057-1065.
14. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005;33(20):e175.
15. Warren P, Taylor D, Martini PG, Jackson J, Bienkowska J. PANP-a new method of gene detection on oligonucleotide expression arrays. IEEE 7th International Conference on BioInfor-matics and BioEngineering. 2007;108-115.
16. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-2553.
17. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7-15.
18. Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol. 2011;2(3):287-294.